Skip to main content
Clinical Trials/NCT02195453
NCT02195453
Unknown
Phase 4

A Randomized,Double-blind,Placebo-Controlled,Multicenter Clinical Trail of Chemotherapy Combined With Yangzhengxiaoji Capsule in Patients With Advanced Non-Small Cell Lung Cancer

Shandong Cancer Hospital and Institute0 sites520 target enrollmentAugust 2014

Overview

Phase
Phase 4
Intervention
Yangzhengxiaoji Capsule
Conditions
Non-Small Cell Lung Cancer
Sponsor
Shandong Cancer Hospital and Institute
Enrollment
520
Primary Endpoint
Lung Cancer Symptom Scale
Last Updated
11 years ago

Overview

Brief Summary

The purpose of this study is to observe quality of life and treatment side effects in patients with advanced non small cell lung cancer (NSCLC) receive chemotherapy and Yangzhengxiaoji capsule.

Registry
clinicaltrials.gov
Start Date
August 2014
End Date
December 2016
Last Updated
11 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Shandong Cancer Hospital and Institute
Responsible Party
Principal Investigator
Principal Investigator

Jinming Yu

Shandong Cancer Hospital and Institute

Shandong Cancer Hospital and Institute

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Arms & Interventions

Yangzhengxiaoji Capsule

Gemcitabine or Pemetrexed Cisplatin Yangzhengxiaoji Capsule four granules t.i.d po

Intervention: Yangzhengxiaoji Capsule

Placebo Capsule

Gemcitabine or Pemetrexed Cisplatin Placebo Capsule four granules t.i.d po

Intervention: Placebo Capsule

Outcomes

Primary Outcomes

Lung Cancer Symptom Scale

Time Frame: 84day

Functional Assessment of Cancer Therapy-Lung scale

Time Frame: 84day

Secondary Outcomes

  • Completion of chemotherapy(84 day)
  • Progression-free survival(84 day)
  • Anti-cancer drugs common grading evaluation of adverse reaction(84day)
  • Objective response rate(84day)

Similar Trials